SCHEMBL6009054

SCHEMBL6009054

CCC(NCC(F)(F)CS(=O)O)c1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.39
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 1/20 0.39
TSHR P16473 1/20 0.39
HSD17B10 Q99714 1/20 0.39
SLC6A9 P48067 1/20 0.36
RIPK1 Q13546 1/20 0.36
EPHX2 P34913 2/20 0.36
NPC1 O15118 1/20 0.36
KCNA5 P22460 2/20 0.35
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
ASPH Q12797 1/20 0.34
KDM8 Q8N371 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
SMN1; SMN2 Q16637 2/20 0.34
CYP1A2 P05177 1/20 0.34
POLB P06746 1/20 0.34
CYP3A4 P08684 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6009865 0.78 KCNA5 (0.42) LMNAALDH1A1KDM4EHPGDTSHR
SCHEMBL6008742 0.73 LMNA (0.40) LMNAALDH1A1KDM4EHPGDTSHR
SCHEMBL13900496 0.72 RIPK1 (0.41) LMNAALDH1A1KDM4EHPGDTSHR
SCHEMBL476492 0.68 LMNA (0.46) LMNAALDH1A1KDM4EHPGDTSHR
SCHEMBL13970878 0.68 LMNA (0.46) LMNAALDH1A1KDM4EHPGDTSHR
SCHEMBL12228438 0.68 LMNA (0.46) LMNAALDH1A1KDM4EHPGDTSHR
SCHEMBL3177566 0.67 LMNA (0.51) LMNAALDH1A1KDM4EHPGDTSHR
SCHEMBL1789777 0.67 ALDH1A1 (0.55) LMNAALDH1A1KDM4EHPGDTSHR
SCHEMBL1789779 0.67 ALDH1A1 (0.55) LMNAALDH1A1KDM4EHPGDTSHR
SCHEMBL15219405 0.66 LMNA (0.50) LMNAALDH1A1KDM4EHPGDTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183800-A1 Methods and fluorinated compositions for treating amyloid-related diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183800-A1 Methods and fluorinated compositions for treating amyloid-related diseases APP, PSEN1, TTR LMNA 50/4885ALDH1A1 1915/4885KDM4E 4725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.